for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shattuck Labs Inc

STTK.OQ

Latest Trade

35.00USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

17.51

 - 

35.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.00
Open
--
Volume
--
3M AVG Volume
--
Today's High
--
Today's Low
--
52 Week High
35.20
52 Week Low
17.51
Shares Out (MIL)
41.74
Market Cap (MIL)
1,360.03
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Shattuck Labs Reports Third Quarter 2020 Financial Results And Recent Business Highlights

Shattuck Labs Says Taylor Schreiber Reported 6.5% Stake In Co

Shattuck Labs Shares Open 30% Above IPO Price In NASDAQ Debut

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shattuck Labs Inc

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of dual-sided fusion proteins. The Company has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The Company's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

Industry

Biotechnology & Drugs

Contact Info

1018 W. 11Th Street, Suite 100

AUSTIN, TX

78703

United States

+1.919.8642700

https://www.shattucklabs.com/

Executive Leadership

Josiah C. Hornblower

Executive Chairman of the Board, Co-Founder

Taylor Schreiber

Chief Executive Officer, Co-Founder, Director

Andrew R. Neill

Vice President - Finance and Corporate Strategy

Casi DeYoung

Chief Business Officer

Lini Pandite

Chief Medical Officer

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020(E)

0.0K
EPS (USD)

2020(E)

-1.894
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up